Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
Go back to Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789| Merck & Co. (NYSE: MRK) | Delayed: 120.76 +1.67 (1.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $119.09 | 52 Week High | $65.46 | |||
| Open | $120.04 | 52 Week Low | $47.97 | |||
| Day High | $122.71 | P/E | 82.15 | |||
| Day Low | $119.95 | EPS | $1.47 | |||
| Volume | 13,179,268 | |||||
